14 August 2018
Visiongain has launched a new pharma report Endometriosis Drug Forecasts and R&D 2017-2027: Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets
The migration of endometrial tissue outside the uterus to other parts of the body is called endometriosis. Rarely heard about, endometriosis is actually a common disease among women. Approximately,10% of women worldwide have endometriosis. The Diagnosis Survey of Endometriosis UK found that young girls and women are not aware of the fact that the pain and other symptoms they face are not normal.
Endometriosis is most commonly found on ovaries, fallopian tubes and the tissues lining the womb, which can lead to fertility problems. Other common places are around pelvis and abdomen such as vagina, bladder or bowel. Rarely, endometriosis can occur in other places such as lungs, brain or breast. Endometriosis affects women during their reproductive life (15-49 years of age). Normally during the menstrual cycle, the thickened womb lining will break down and blood will leave your body. However, in case of endometriosis, all other tissue which has moved outside the womb will also gets thickened and release blood with no route to escape the body. This can lead to pain, swelling and scarring. Endometriosis is a chronic inflammatory, oestrogen-dependent disease that grows with every menstrual cycle.
The real cause of endometriosis is unknown. There are many theories like retrograde menstruation, genetic predisposition, lymphatic or circulatory spread, immune dysfunction environmental causes and metaplasia but none fully explain why it occurs. Many organisations and societies all over the world are focusing in increasing the awareness and raising the funds to support women with endometriosis and this increasing recognition will grow the market over the next decade.
The lead visiongain report analyst for this report commented “Endometriosis is one of the most widespread chronic conditions in women affecting around 176 million of them around the world. Current diagnostic and treatment strategies possess limitations, reportedly causing side effects and inconvenience to patients. Many pharmaceutical companies are developing novel medicines with different therapeutic targets for treating endometriosis. The need for advances in medical technologies for better diagnoses and treatment for endometriosis expands, giving opportunities for companies and healthcare providers. A large population of affected women remain undiagnosed due to lack of knowledge about the disease. Better treatment of endometriosis depends on greater understanding of the disease in medical science and the pharma industry, as well as more awareness programmes by healthcare providers.”
Leading companies who are active in the Endometriosis market and are featured in the report include AbbVie, Pfizer, Bayer HealthCare, AstraZeneca, Astellas, Takeda, Repros Therapeutics, Euroscreen, Kissei Pharmaceutical and Addex Therapeutics
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.